O.J. Brigance died on March 27, 2026, at age 56, following a 19-year fight with ALS. He was the Ravens' senior advisor to player engagement and a former linebacker on the team's Super Bowl XXXV roster. Brigance publicly disclosed his ALS diagnosis in 2008 and continued working for the franchise for the rest of his life. The Ravens announced his death; the team and the Brigance Brigade Foundation, which he and his wife Chanda founded, confirmed it.
Brigance's case became one of the most documented long-term ALS survival stories in American sport. He outlived the typical post-diagnosis prognosis by more than a decade, and he did so while remaining visibly employed by an NFL team. That combination, not the diagnosis alone, is why his case drew attention from neurologists as well as fans.
The biology Brigance was fighting
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that kills upper and lower motor neurons. Upper motor neurons run from the brain's cortex to the spinal cord. Lower motor neurons run from the spinal cord to muscle fibers. When either set dies, muscles lose the signal that keeps them alive and moving.
The disease is not primarily a muscle disorder. It is a wiring failure. Muscles weaken because the neurons that command them degenerate, and the degeneration spreads as neighboring motor neurons fail. That is why ALS produces both spasticity (from upper neuron loss) and fasciculations, or muscle twitches (from lower neuron loss), in the same patient.
Most cases are sporadic, meaning no known inherited cause. Roughly 5 to 10 percent are familial, tied to genes including C9orf72, SOD1, TARDBP, and FUS. The C9orf72 repeat expansion is the most common known genetic cause in people of European descent. Brigance's specific genetic status was not public, and no responsible conclusion can be drawn about it.
The disease typically spares the senses, the bladder, and the eye muscles for long stretches. Cognition is usually preserved, though a minority develop frontotemporal dementia. That preservation is part of what makes ALS cruel: the mind often stays intact while the body loses access to it.
Why 19 years is an outlier
Median survival after ALS symptom onset is roughly 2 to 5 years, and median survival after diagnosis is somewhat shorter because diagnosis lags onset by about a year on average. About 20 percent of patients live beyond 5 years. Roughly 10 percent reach 10 years. Survival past 15 years is uncommon enough that long-term survivors are studied as a distinct group.
Brigance was diagnosed publicly in 2008 and died in 2026, a span of about 18 years from disclosure and 19 years framed as his fight. Either way, he sits far out in the right tail of the survival curve. Long survival is associated with several features: younger age at onset, limb onset rather than bulbar (speech and swallowing) onset, slower rate of functional decline in the first year, and supportive multidisciplinary care.
None of those factors is a guarantee, and each is probabilistic. A patient with every favorable feature can still decline fast; a patient with none can still live long. That unpredictability is one of the hardest parts of ALS care, and it is a reason clinicians avoid giving patients a single firm number.
What made Brigance's course notable was not just duration but function. He continued in a front-office role, used assistive technology, and remained a public face of the franchise. Sustained employment with ALS is possible but depends heavily on disease trajectory, workplace accommodation, and access to care.
Quantified context: what ALS costs and how often it occurs
ALS affects roughly 5 to 7 people per 100,000 in the United States each year, depending on the dataset and case definition. Prevalence, the number living with the disease at a given time, is higher, commonly estimated in the range of 15,000 to 30,000 Americans. The CDC's National ALS Registry exists specifically because these counts are hard to pin down; the registry combines self-report, Medicare, and other data sources.
The economic burden is large and front-loaded. Out-of-pocket costs for families commonly run tens of thousands of dollars per year, driven by home modifications, mobility equipment, communication devices, and caregiver hours. Medicare and Medicaid cover parts of this; they do not cover all of it. For context, a single power wheelchair can cost USD 15,000 to USD 40,000 before insurance, and a communication device with eye-tracking can run USD 10,000 or more.
The table below sets long-survivor status against common reference points, so the numbers are not read in isolation.
| Survival frame | Approximate share of patients | What it means in practice |
|---|---|---|
| Under 2 years from onset | A substantial minority | Fast decline; early planning for ventilation and feeding decisions |
| 2 to 5 years | Around half | The typical window; most care planning assumes this range |
| Beyond 5 years | About 20 percent | Multidisciplinary care and equipment access matter most here |
| Beyond 10 years | About 10 percent | Long-survivor phenotype; often limb onset and younger age |
| Beyond 15 years | Small single digits | Rare; Brigance's course sits here |
| Beyond 20 years | Very rare | Documented but exceptional; not a planning assumption |
The units are US patients, and the percentages are rounded ranges drawn from cohort studies and clinical summaries, not a single registry. Treat them as orientation, not prognosis.
The long-survivor edge cases
Long survival in ALS is real but is not simply "a slower version of the same disease." Some long survivors plateau for years, then decline. Others have a course dominated by one region, such as the arms, while breathing and swallowing stay stable far longer than expected. A small number are reclassified after genetic testing or after a second opinion reveals a mimic, such as a multifocal motor neuropathy or a cervical myelopathy.
That reclassification point is the professional caveat worth stating plainly. ALS is a clinical diagnosis with no single confirmatory blood test, and diagnostic error rates are not trivial. Expert centers use electromyography, imaging, and lab panels to exclude mimics. A patient labeled with ALS who survives 15 years should prompt a review of the original diagnosis, though many long survivors are confirmed on review.
The counterintuitive detail: respiratory function, not limb strength, usually determines survival. Patients and families often track arm and leg weakness because it is visible. Clinicians track forced vital capacity and other breathing measures because they predict outcomes better. A patient who can still walk but whose breathing capacity is falling is in more danger than the reverse.
Misconceptions worth correcting
ALS is not contagious, and it is not caused by an injury, a vaccine, or a single lifestyle choice. NFL participation has been studied as a possible risk factor for neurodegenerative disease, and the evidence is mixed and methodologically difficult; contact-sport exposure and ALS risk remain an active research question, not a settled causal link. Brigance's own case does not resolve that question either way.
Another misconception: long survival means the disease "stopped." It does not. It means the rate of loss was slower, or the plateau lasted longer, or care compensated well. The underlying motor neuron degeneration is generally progressive.
A third: hospice and aggressive treatment are opposites. They are not. Palliative care can be delivered alongside disease-modifying therapy and has been shown to improve quality of life and, in some studies, survival. Earlier palliative involvement is a feature of high-quality ALS care, not a sign of giving up.
Red flags that warrant urgent clinical attention in any ALS patient:
New or worsening shortness of breath at rest, or morning headaches suggesting poor overnight ventilation. Rapid weight loss or new choking episodes, which can signal bulbar progression and aspiration risk. A sudden drop in forced vital capacity on interval testing, even if the patient feels unchanged. New falls or fractures, which can accelerate decline and complicate care. Unexplained fever or respiratory infection, which can be life-threatening with weakened breathing muscles.
What patients and families can actually do
Practical steps, in rough order of leverage:
Get diagnosed and followed at a multidisciplinary ALS clinic. Specialty clinics are associated with better survival and quality of life than fragmented care, and they coordinate neurology, pulmonology, speech, nutrition, and social work in one place. Establish a baseline breathing test early and repeat it on a schedule your clinician sets. Forced vital capacity and sniff nasal inspiratory pressure are common measures; trends matter more than single values. Ask about disease-modifying options and clinical trials at diagnosis, not later. Availability and eligibility change over time, so the specific menu is a conversation for your neurologist, not a fixed list in an article. Plan communication and mobility equipment before you need it. Procurement and insurance approval take weeks to months; starting early avoids gaps. Put legal and financial planning in motion early: advance directives, power of attorney, and insurance review. These are not end-of-life-only documents; they preserve choice. Connect with a caregiver support network. Caregiver burnout is a real clinical variable that affects patient outcomes.
The reconciliation point on thresholds: survival statistics, functional scales, and breathing measures use different cutoffs, and no single number should drive a decision. A forced vital capacity below 50 percent predicted is a common trigger for noninvasive ventilation discussion, but the right threshold is patient-specific and set by a clinician who knows the trajectory. Ranges are guidance; trends are signal.
What the science still cannot say
No one can predict an individual's ALS course from population data. The long-survivor literature describes groups, not individuals, and the mechanisms behind slow progression are incompletely understood. Genetic subtypes explain some of the variance; much remains unexplained, including environmental and immunological factors under study.
Brigance's 19-year course is a genuine outlier and a meaningful public story, but it is not a template. Most patients do not follow it, and framing it as a model can distort expectations. The honest summary is that ALS remains a progressive, fatal disease with a wide survival range, and that expert multidisciplinary care, early breathing management, and aggressive symptom control are the interventions with the best evidence for improving both length and quality of life.
For anyone facing this disease, the actionable message is not a promise of longevity. It is that structured care changes the experience of the illness, and that planning early preserves options later. That is a claim the evidence supports; a specific survival prediction is not.
This article is general educational information about ALS and is not a diagnosis, treatment plan, or substitute for medical advice. It does not promise any outcome, and individual cases vary widely. Consult a qualified neurologist or ALS specialty clinic for personal medical decisions, and contact local emergency services if someone is in immediate danger.